LON:COIL Roquefort Therapeutics H2 2025 Earnings Results & Report GBX 6 -0.22 (-3.54%) As of 07:37 AM Eastern Roquefort Therapeutics reported H2 2025 earnings on May 6, 2026. The company reported EPS of -GBX 2.19. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterH2 2025Report DateMay 6, 2026TimeBefore Market OpensConference Call DateMay 5, 2026Conference Call2:00 AM ET Roquefort Therapeutics EPS ResultsActual EPS-GBX 2.19Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ARoquefort Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesAnnual ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report Roquefort Therapeutics H2 2025 Earnings FAQ Did Roquefort Therapeutics beat earnings estimates for H2 2025? Roquefort Therapeutics (LON:COIL) reported earnings of -GBX 2.19 per share for H2 2025. The report was announced on Wednesday, May 6, 2026. Roquefort Therapeutics Earnings HeadlinesCoiled Therapeutics progresses AO-252 testing enrolmentSeptember 22, 2026 | marketscreener.comMCoiled Therapeutics PLCApril 1, 2026 | barrons.comWhy This Overlooked Mineral Could Define AI's FutureChina controls 90% of the production of two critical minerals essential to AI data centers, semiconductors, and quantum computing. In 2024, AI data centers consumed as much energy as New York and Chicago combined, underscoring the urgency of securing domestic supply. Jamie Dimon and Condoleezza Rice are now backing Project Phoenix, a major push to rebuild America's mineral supply chain.October 12 at 1:00 AM | Weiss Ratings (Ad)Roquefort springs over to AIM from Main Market as Coiled TherapeuticsMarch 27, 2026 | lse.co.ukCoiled Therapeutics' Dr Sotirios Stergiopoulos on Roquefort RTO, AO-252 cancer trial updateMarch 9, 2026 | uk.finance.yahoo.comSmall cap idea: Why this £40m bet on an emerging cancer treatment may be perfectly timedMarch 9, 2026 | msn.comSee More Roquefort Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Roquefort Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Roquefort Therapeutics and other key companies, straight to your email. Email Address About Roquefort TherapeuticsCoiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals. https://coiledplc.com/View Roquefort Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
